Uchenna Ogbuokiri, MD
Geriatric Medicine · Saint Louis, MONPI 1467516757
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $756 and has fallen 82.4% since, to $133 in 2025.
Across 190 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$534
- Novo Nordisk$511
- GSK$384
- Smith+Nephew$311
- AstraZeneca$238
- Pfizer$166
- plus $956 from 18 others
What the payments were for
- Food & beverage$3,100100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 32 | $534 |
| Novo Nordisk | 31 | $511 |
| GSK | 28 | $384 |
| Smith+Nephew | 12 | $311 |
| AstraZeneca | 14 | $238 |
| Pfizer | 9 | $166 |
| AbbVie(2 entities) | 10 | $159 |
| Novartis | 8 | $146 |
| Boehringer Ingelheim | 8 | $134 |
| Sunovion Pharmaceuticals Inc. | 12 | $133 |
| Amarin Pharma, Inc. | 5 | $73 |
| Integra Lifesciences Corporation | 4 | $57 |
| Bardy Diagnostics, Inc. | 3 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Amgen | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $27 |
| Verona Pharma, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Gilead | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $12 |
| Medtronic | 1 | $11 |
| Hologic Sales And Service, LLC | 1 | $11 |
| Aroa Biosurgery Incorporated | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Santyl$121
- PICO 7 Single Use Negative Pressure Wound Therapy$121
- Allevyn Life$121
- Durafiber$121
- Acticoat Range$121
How this compares
$3,100 in reported general payments places this provider in the 85th percentile of 76 geriatric medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 81 | $99,916 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $64,453 |
| FarxigaDapagliflozin Propanediol | 52 | $32,804 |
| JanuviaSitagliptin Phosphate | 61 | $30,780 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $28,623 |
| OzempicSemaglutide | 20 | $28,353 |
| TrulicityDulaglutide | 29 | $27,638 |
| EntrestoSacubitril/Valsartan | 32 | $18,829 |
| TradjentaLinagliptin | 26 | $17,917 |
| EliquisApixaban | 24 | $16,613 |
| Risperdal ConstaRisperidone Microspheres | 13 | $16,524 |
| XareltoRivaroxaban | 38 | $12,332 |
| Paliperidone ErPaliperidone | 90 | $12,293 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $11,846 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $7,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $511 | $128,268101 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $384 | $93,076114 claims |
| AstraZenecaFarxiga | $238 | $32,80452 claims |
| Boehringer IngelheimTradjenta, Combivent Respimat | $134 | $29,76341 claims |
| Lilly USA, LLCTrulicity | $534 | $27,63829 claims |
| NovartisEntresto | $146 | $18,82932 claims |
| PfizerEliquis | $166 | $16,61324 claims |
| AbbVieLinzess | $159 | $7,67914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 76 geriatric medicine providers in Missouri.
Other geriatric medicine in Saint Louis
- Angela SanfordSaint Louis$15K
- Ellen BinderSaint Louis$4K
- Poonam JainSaint Louis$4K
- Charles CreceliusSaint Louis$3K
- Seema IyerSaint Louis$2K
- Hanish Sampath KumarSaint Louis$2K
- Richard OneillSaint Louis$1K
- Mark GunbySaint Louis$1K
- David CarrSaint Louis$1K
- Susan ReedsSaint Louis$725
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.